Search Results - Hasmann, Max

  • Showing 1 - 9 results of 9
Refine Results
  1. 1
    Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement‐dependent anti‐tumor activity of trastuzumab and pertuzumab

    Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement‐dependent anti‐tumor activity of trastuzumab and pertuzumab by Mamidi, Srinivas, Cinci, Marc, Hasmann, Max, Fehring, Volker, Kirschfink, Michael

    Published 2013
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  2. 2
    Pertuzumab Increases 17-AAG-Induced Degradation of ErbB2, and This Effect Is Further Increased by Combining Pertuzumab with Trastuzumab

    Pertuzumab Increases 17-AAG-Induced Degradation of ErbB2, and This Effect Is Further Increased by Combining Pertuzumab with Trastuzumab by Hughes, Juliana Bentes, Rødland, Marianne Skeie, Hasmann, Max, Madshus, Inger Helene, Stang, Espen

    Published 2012
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  3. 3
    Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer

    Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer by Collins, Denis, Jacob, Wolfgang, Cejalvo, Juan Miguel, Ceppi, Maurizio, James, Ian, Hasmann, Max, Crown, John, Cervantes, Andrés, Weisser, Martin, Bossenmaier, Birgit

    Published 2017
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  4. 4
    Disentangling ERBB Signaling in Breast Cancer Subtypes—A Model-Based Analysis

    Disentangling ERBB Signaling in Breast Cancer Subtypes—A Model-Based Analysis by Kemmer, Svenja, Berdiel-Acer, Mireia, Reinz, Eileen, Sonntag, Johanna, Tarade, Nooraldeen, Bernhardt, Stephan, Fehling-Kaschek, Mirjam, Hasmann, Max, Korf, Ulrike, Wiemann, Stefan, Timmer, Jens

    Published 2022
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  5. 5
    Assessment of susceptible chemical modification sites of trastuzumab and endogenous human immunoglobulins at physiological conditions

    Assessment of susceptible chemical modification sites of trastuzumab and endogenous human immunoglobulins at physiological conditions by Schmid, Ingrid, Bonnington, Lea, Gerl, Monika, Bomans, Katrin, Thaller, Anna Louisa, Wagner, Katharina, Schlothauer, Tilman, Falkenstein, Roberto, Zimmermann, Boris, Kopitz, Jürgen, Hasmann, Max, Bauss, Frieder, Haberger, Markus, Reusch, Dietmar, Bulau, Patrick

    Published 2018
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  6. 6
    Stromal NRG1 in luminal breast cancer defines pro-fibrotic and migratory cancer-associated fibroblasts

    Stromal NRG1 in luminal breast cancer defines pro-fibrotic and migratory cancer-associated fibroblasts by Berdiel-Acer, Mireia, Maia, Ana, Hristova, Zhivka, Borgoni, Simone, Vetter, Martina, Burmester, Sara, Becki, Corinna, Michels, Birgitta, Abnaof, Khalid, Binenbaum, Ilona, Bethmann, Daniel, Chatziioannou, Aristotelis, Hasmann, Max, Thomssen, Christoph, Espinet, Elisa, Wiemann, Stefan

    Published 2021
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  7. 7
    A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer

    A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small... by Cejalvo, Juan-Miguel, Jacob, Wolfgang, Fleitas Kanonnikoff, Tania, Felip, Enriqueta, Navarro Mendivil, Alejandro, Martinez Garcia, Maria, Taus Garcia, Alvaro, Leighl, Natasha, Lassen, Ulrik, Mau-Soerensen, Morten, Adessi, Celine, Michielin, Francesca, James, Ian, Ceppi, Maurizio, Hasmann, Max, Weisser, Martin, Cervantes, Andrés

    Published 2019
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  8. 8
    Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer

    Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-... by Schneeweiss, Andreas, Park-Simon, Tjoung-Won, Albanell, Joan, Lassen, Ulrik, Cortés, Javier, Dieras, Veronique, May, Marcus, Schindler, Christoph, Marmé, Frederik, Cejalvo, Juan Miguel, Martinez-Garcia, Maria, Gonzalez, Iria, Lopez-Martin, Jose, Welt, Anja, Levy, Christelle, Joly, Florence, Michielin, Francesca, Jacob, Wolfgang, Adessi, Céline, Moisan, Annie, Meneses-Lorente, Georgina, Racek, Tomas, James, Ian, Ceppi, Maurizio, Hasmann, Max, Weisser, Martin, Cervantes, Andrés

    Published 2018
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  9. 9
    Effects of HER family-targeting tyrosine kinase inhibitors on antibody-dependent cell-mediated cytotoxicity in HER2-expressing breast cancer

    Effects of HER family-targeting tyrosine kinase inhibitors on antibody-dependent cell-mediated cytotoxicity in HER2-expressing breast cancer by Collins, Denis M., Madden, Stephen F., Gaynor, Nicola, AlSultan, Dalal, Le Gal, Marion, Eustace, Alex J., Gately, Kathy A., Hughes, Clare, Davies, Anthony M., Mahgoub, Thamir, Ballot, Jo, Toomey, Sinead, O’Connor, Darran P., Gallagher, William M., Holmes, Frankie A., Espina, Virginia, Liotta, Lance, Hennessy, Bryan T., O’Byrne, Kenneth J., Hasmann, Max, Bossenmaier, Birgit, O’Donovan, Norma, Crown, John

    Published 2020
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:

Search Tools: